Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure; and reldesemtiv, a skeletal muscle troponin activator, which is in Phase III clinical trial to treat amyotrophic lateral sclerosis and spinal muscular atrophy. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy; and CK-3772271, a small molecule cardiac myosin inhibitor that is in Phase I clinical trial. Cytokinetics, Incorporated has a strategic alliance with Astellas Pharma Inc. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
Over the last 12 months, insiders at Cytokinetics, Incorporated have bought $0 and sold $24.97M worth of Cytokinetics, Incorporated stock.
On average, over the past 5 years, insiders at Cytokinetics, Incorporated have bought $3.28M and sold $20.36M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 118,413 shares for transaction amount of $1.13M was made by BVF PARTNERS L P/IL (10 percent owner) on 2019‑12‑11.
2024-06-25 | Sale | Malik Fady Ibraham | EVP Research & Development | 7,300 0.0065% | $53.72 | $392,143 | -3.66% | |
2024-06-17 | Sale | Blum Robert I | President & CEO | 22,500 0.0194% | $52.60 | $1.18M | +0.17% | |
2024-06-17 | Sale | PARSHALL B LYNNE | director | 5,000 0.0043% | $52.55 | $262,750 | +0.17% | |
2024-06-11 | Sale | Malik Fady Ibraham | EVP Research & Development | 7,788 0.0068% | $53.04 | $413,106 | -0.79% | |
2024-06-10 | Sale | Bhanji Muna | director | 2,000 0.0017% | $52.07 | $104,140 | -1.99% | |
2024-06-04 | Sale | Blum Robert I | President & CEO | 22,500 0.0198% | $48.85 | $1.1M | +9.69% | |
2024-06-03 | Sale | Wong Robert | VP, Chief Accounting Officer | 13,011 0.0111% | $48.88 | $635,978 | +5.93% | |
2024-06-03 | Sale | PARSHALL B LYNNE | director | 5,000 0.0043% | $48.64 | $243,200 | +5.93% | |
2024-06-03 | Sale | Harrington Robert Arthur | director | 1,580 0.0013% | $48.64 | $76,851 | +5.93% | |
2024-05-07 | Sale | Malik Fady Ibraham | EVP Research & Development | 15,547 0.0149% | $65.11 | $1.01M | -18.01% | |
2024-04-25 | Sale | HENDERSON JOHN T | director | 10,562 0.0099% | $64.54 | $681,671 | -16.42% | |
2024-04-09 | Sale | Malik Fady Ibraham | EVP Research & Development | 32,605 0.0313% | $74.31 | $2.42M | -20.16% | |
2024-03-05 | Sale | Malik Fady Ibraham | EVP Research & Development | 32,604 0.032% | $67.56 | $2.2M | -3.09% | |
2024-02-14 | Sale | HENDERSON JOHN T | director | 5,000 0.0049% | $76.48 | $382,400 | -14.68% | |
2024-02-13 | Sale | Blum Robert I | President & CEO | 12,500 0.0124% | $76.85 | $960,625 | -15.25% | |
2024-02-06 | Sale | Malik Fady Ibraham | EVP Research & Development | 32,605 0.0336% | $79.30 | $2.59M | -18.34% | |
2024-01-31 | Sale | Blum Robert I | President & CEO | 12,500 0.0129% | $79.57 | $994,625 | -15.77% | |
2024-01-19 | Sale | Blum Robert I | President & CEO | 12,500 0.0128% | $81.42 | $1.02M | -16.94% | |
2024-01-12 | Sale | HENDERSON JOHN T | director | 5,000 0.0051% | $85.14 | $425,700 | -21.78% | |
2024-01-04 | Sale | Malik Fady Ibraham | EVP Research & Development | 15,678 0.0159% | $86.98 | $1.36M | -22.74% |
Blum Robert I | President & CEO | 416645 0.4506% | $51.75 | 0 | 191 | |
Malik Fady Ibraham | EVP Research & Development | 133004 0.1458% | $51.75 | 0 | 70 | |
HENDERSON JOHN T | director | 32070 0.0435% | $51.75 | 1 | 10 | +75.35% |
Wong Robert | VP, Chief Accounting Officer | 16653 0.0253% | $51.75 | 0 | 4 | |
WIERENGA WENDALL | director | 18653 0.019% | $51.75 | 0 | 6 | |
Bhanji Muna | director | 17631 0.0143% | $51.75 | 0 | 2 | |
Harrington Robert Arthur | director | 15541 0.0136% | $51.75 | 0 | 1 | |
PARSHALL B LYNNE | 20600 0.0102% | $51.75 | 0 | 7 | ||
SCHMERTZLER MICHAEL | director | 4340923 4.4271% | $51.75 | 1 | 8 | +68.65% |
Eastern Capital LTD | 10 percent owner | 2883845 2.9411% | $51.75 | 1 | 0 | |
DOW STEPHEN M | director | 1421052 1.4493% | $51.75 | 9 | 1 | <0.0001% |
BVF PARTNERS L P/IL | 463244 0.4724% | $51.75 | 2 | 2 | +74.11% | |
SPUDICH JAMES A | director | 180600 0.1842% | $51.75 | 0 | 24 | |
Cragg David | Chief HR & Admin Officer | 138704 0.1415% | $51.75 | 0 | 7 | |
SCHLOSSBERG MARK A | SVP - Legal & General Counsel | 103408 0.1055% | $51.75 | 0 | 4 | |
HEIDRICH A GRANT III | director | 93755 0.0956% | $51.75 | 0 | 3 | |
Jaw Ching | SVP Finance & CFO | 67184 0.0685% | $51.75 | 0 | 6 | |
Morgan Bradley Paul | SVP Drug Discovery & Early Dev | 46441 0.0474% | $51.75 | 0 | 1 | |
MORGANS DAVID J JR | EVP-Preclinical R&D | 42000 0.0428% | $51.75 | 0 | 27 | |
GAGE L PATRICK | director | 28932 0.0295% | $51.75 | 4 | 8 | +19.97% |
WOLFF ANDREW A | SVP & CMO | 21261 0.0217% | $51.75 | 0 | 1 | |
TRAUTMAN JAY K | VP, Discovery Research | 17896 0.0183% | $51.75 | 0 | 14 | |
McDowell Caryn Gordon | GC & Chief Compliance Officer | 15000 0.0153% | $51.75 | 0 | 5 | |
Kaye Edward M. MD | 12576 0.0128% | $51.75 | 0 | 3 | ||
SMITH SANDFORD D | 12170 0.0124% | $51.75 | 0 | 18 | ||
COSTA SANTO J | 10000 0.0102% | $51.75 | 0 | 8 | ||
Sabry James H | 0 0% | $51.75 | 0 | 41 |
BlackRock | $870.4M | 10.84 | 12.41M | -22.9% | -$258.52M | 0.02 | |
Fidelity Investments | $764.28M | 9.51 | 10.9M | -16.2% | -$147.7M | 0.05 | |
The Vanguard Group | $700.89M | 8.73 | 10M | -9.26% | -$71.5M | 0.01 | |
T Rowe Price Investment Management Inc | $359.07M | 4.47 | 5.12M | +129.72% | +$202.77M | 0.22 | |
Bank of America | $334.96M | 4.17 | 4.78M | +1,690.91% | +$316.26M | 0.03 | |
State Street | $316.92M | 3.95 | 4.52M | -23.3% | -$96.26M | 0.01 | |
Wellington Management Company | $279.14M | 3.48 | 3.98M | -38.64% | -$175.77M | 0.05 | |
T. Rowe Price | $205.49M | 2.56 | 2.93M | -9.66% | -$21.97M | 0.03 | |
Marshall Wace | $179.26M | 2.23 | 2.56M | +308.38% | +$135.36M | 0.23 | |
RTW Investments, LP | $177.03M | 2.2 | 2.53M | 0% | +$0 | 2.62 | |
Geode Capital Management | $157.57M | 1.96 | 2.25M | +7.51% | +$11.01M | 0.01 | |
Boxer Capital, LLC | $147.23M | 1.83 | 2.1M | 0% | +$0 | 7.36 | |
AllianceBernstein | $124.1M | 1.55 | 1.77M | +1,347.94% | +$115.53M | 0.04 | |
PFM Health Sciences | $123.2M | 1.53 | 1.76M | 0% | +$0 | 3.4 | |
Polar Capital | $112.57M | 1.4 | 1.61M | +13.3% | +$13.22M | 0.62 | |
Armistice Capital Llc | $106.97M | 1.33 | 1.53M | New | +$106.97M | 1.28 | |
Invesco | $92.37M | 1.15 | 1.32M | +6% | +$5.23M | 0.02 | |
Northern Trust | $77.92M | 0.97 | 1.11M | +5.25% | +$3.89M | 0.01 | |
Hudson Bay Capital Management LP | $75.72M | 0.94 | 1.08M | New | +$75.72M | 1.97 | |
Melqart Asset Management UK Ltd | $68.95M | 0.86 | 983,395 | New | +$68.95M | 6.04 | |
Morgan Stanley | $66.95M | 0.83 | 954,858 | -60.24% | -$101.43M | 0.01 | |
BNY Mellon | $63.1M | 0.79 | 900,054 | -24.1% | -$20.04M | 0.01 | |
Millennium Management LLC | $56.85M | 0.71 | 810,910 | -32.39% | -$27.23M | 0.04 | |
Janus Henderson | $55.9M | 0.7 | 797,372 | -68.95% | -$124.16M | 0.03 | |
Charles Schwab | $54.37M | 0.68 | 775,556 | -1.82% | -$1.01M | 0.01 | |
Barclays | $53.44M | 0.67 | 762,247 | +64.02% | +$20.86M | 0.02 | |
Voloridge Investment Management, LLC | $53.31M | 0.66 | 760,319 | New | +$53.31M | 0.12 | |
Brown Advisory | $53.25M | 0.66 | 759,534 | New | +$53.25M | 0.07 | |
Westfield Capital Management Co Lp | $51.28M | 0.64 | 731,386 | New | +$51.28M | 0.27 | |
Hood River Capital Management LLC | $48.84M | 0.61 | 696,647 | +24.18% | +$9.51M | 1.09 | |
Goldman Sachs | $48.48M | 0.6 | 691,449 | -15.21% | -$8.69M | 0.01 | |
JPMorgan Chase | $48.24M | 0.6 | 688,104 | +141.95% | +$28.3M | <0.01 | |
OrbiMed | $47.86M | 0.6 | 682,700 | New | +$47.86M | 0.98 | |
Balyasny Asset Management Llc | $47.33M | 0.59 | 675,062 | +63.4% | +$18.36M | 0.13 | |
Susquehanna International Group | $40.42M | 0.5 | 576,477 | -9.29% | -$4.14M | 0.04 | |
Franklin Templeton Investments | $39.63M | 0.49 | 565,296 | -14.44% | -$6.69M | 0.01 | |
Citadel Advisors LLC | $39.32M | 0.49 | 560,902 | +105.77% | +$20.21M | 0.03 | |
Fisher Asset Management Llc | $37.78M | 0.47 | 538,797 | +0.51% | +$192,872.60 | 0.02 | |
Laurion Capital Management LP | $36.45M | 0.45 | 519,918 | New | +$36.45M | 1.02 | |
Artal Group S A | $35.52M | 0.44 | 506,584 | -58.28% | -$49.62M | 0.19 | |
Nuveen | $35.03M | 0.44 | 499,601 | +45.4% | +$10.94M | 0.01 | |
Candriam S C A | $34.57M | 0.43 | 493,029 | +84.49% | +$15.83M | 0.22 | |
Readystate Asset Management Lp | $32.64M | 0.41 | 465,498 | +726.82% | +$28.69M | 1.82 | |
Integral Health Asset Management Llc | $31.55M | 0.39 | 450,000 | +125% | +$17.53M | 3.13 | |
Hrt Financial Llc | $30.2M | 0.38 | 430,821 | +903.85% | +$27.2M | 0.19 | |
Ensign Peak Advisors Inc | $29.74M | 0.37 | 424,259 | -0.38% | -$112,456.44 | 0.05 | |
American Century Investments | $29.16M | 0.36 | 415,854 | -56.99% | -$38.64M | 0.02 | |
DAFNA Capital Management, LLC | $27.91M | 0.35 | 398,100 | -0.47% | -$133,209.00 | 6.49 | |
Hap Trading Llc | $27.73M | 0.35 | 395,529 | New | +$27.73M | 8.6 | |
Renaissance Technologies | $25.66M | 0.32 | 365,967 | +917.51% | +$23.14M | 0.04 |